Last Orders: What you might have missed today on the ASX
Link copied to
This is absolutely the last time we throw back to 2017 when JPMorgan CEO Jamie Dimon called Bitcoin a “fraud”. Maybe.
But it’s hard to resist when JPMorgan insists on putting out increasingly positive notes about the cryptocurrency that simply won’t die.
Late last week, PayPal announced it would allow its users to buy, sell and exchange Bitcoin. That sent it even higher for 2020, after a near-70 per cent run has it now topping the $US13,000 mark.
Dimon once said he’d fire any JPMorgan traders caught trading Bitcoin “in a second”.
“It is against our rules and they are stupid, and both are dangerous,” he said.
Now, in its latest update on BTC, JPMorgan has noted Bitcoin has “considerable” upside, and suggest that Millennials’ preference for it over gold make BTC a legitimate “alternative” currency.
Hoo boy. Here’s a few more brave bets you might have missed today.
– Kyckr (ASX:KYK) shares have been up around nine per cent to 8.3c after the regulatory technology (RegTech) company said it brought in $646,000 in revenue in the three months to September 30, up 16 per cent from a year ago and in line with the three months prior. Its strategic focus has switched to corporate clients, rather “pay as you go” retail website activities.
– Volpara Health Technologies (ASX:VHR) fell 1.3 per cent to $1.48 after announcing a partnership with the Sheila R. Veloz Breast Center at Henry Mayo Newhall Hospital in California to bring image-enhanced reporting directly to women. Patients getting a mammogram at the hospital will receive a letter complete with thumbnail pictures of their breasts, ranking their breast density from an “a” to a “d”. Dense breasts can camouflage cancer on mammograms.
– Prescient Therapeutics (ASX:PTX) fell 1.6 per cent to 6c after receiving a new US patent covering methods for using a specific biomarker to stratify breast cancer patients and identify those most likely to respond to treatment with its anti-cancer compound PTX-100. Once granted the patent is expected to be valid until 2031.
– Little Green Pharma (ASX:LGP) was flat at 34c after the WA cannabis producer announced it had finished the September quarter with $4.1 million, after receiving record sales revenue of $1.29 million. The company said it had sold 8,500 units, up from 41 per cent the previous quarter.
– Strike Resources (ASX:SRK) shares were down 4.6 per cent to 10c after the says it has WA junior explorer said it had finishing sampling 50 pits across 8.1 hectares at its Paulsens East Iron Ore Project. Samples have been sent to ALS Laboratories in Perth for analysis.
– Golden Rim Resources (ASX:GMR) shares fell 12.5 per cent to 1.4c after the West African gold explorer announced it had increased its estimate of the mineral resources at its Kouri gold project in Burkina Faso by 43 per cent, to 310,000 ounces of gold. Drilling will re-commence this calendar quarter, the company said.
Back out Tuesday:
HGL (ASX:HNG) – capital raising
Cauldron Energy (ASX:CXU) – capital raising
Resources & Energy Group (ASX:REZ) – capital raising
Back out Wednesday:
Clinuvel Pharmaceutivals (ASX:CUV) – regulatory decision on SCENESSE
Dampier Gold (ASX:DAU) – exploration results
K2fly (ASX:K2F) – acquisition
E2 Metals (ASX:E2M) – drilling results
Protean Energy (ASX:POW) – capital raising
Trimantium GrowthOps (ASX:TGO) – ASX delisting
Openlearning (ASX:OLL) – capital raising
At Stockhead we tell it like it is. While Strike Resources is a Stockhead advertiser, it did not sponsor this article.